
TOKYO -- Japan will not be able to receive a stable supply of promising coronavirus therapy remdesivir from its U.S. developer to treat all patients in need, Nikkei learned Friday.
Gilead Sciences to distribute enough to cover 140,000 patients worldwide
TOKYO -- Japan will not be able to receive a stable supply of promising coronavirus therapy remdesivir from its U.S. developer to treat all patients in need, Nikkei learned Friday.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.